Trademarkia Logo

United Kingdom

£
Registered

on 19 Dec 2019

Last Applicant/ Owned by

Evelo Biosciences, Inc.

620 Memorial Drive, Suite 200W

Cambridge, , 02139

Serial Number

UK00918169875 filed on 19th Dec 2019

Registration Number

UK00918169875 registered on
22nd May 2020

Correspondent Information

Urquhart-Dykes & Lord LLP

Euston House, 24 Eversholt Street

London,

NW1 1AD

EVELO

pharmaceuticals used to prevent disease in the nature of cancer, cancer symptoms, cancer-related diseases and side effects of cancer therapies; pharma Read More

Classification Information


Class [5]
Pharmaceutical Products


Pharmaceuticals used to prevent disease in the nature of cancer, cancer symptoms, cancer-related diseases and side effects of cancer therapies; Pharmaceuticals used to prevent disease in the nature of inflammation, neuro-inflammation, and autoimmune diseases; pharmaceuticals used to prevent disease in the nature of allergies and disrupted microbial community associated with allergies; Pharmaceuticals used to prevent disease in the nature of metabolic disorders; pharmaceuticals used to prevent cardiovascular, neuro-degenerative, and neuro-psychiatric diseases; pharmaceuticals used to treat and cure neoplastic conditions, pre-neoplastic conditions and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to treat and cure inflammation, neuro-inflammation, and autoimmune diseases and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to treat and cure allergies and disrupted microbial community associated with allergies in human and animal subjects; pharmaceuticals used to treat and cure metabolic disorders and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to treat and cure cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of neoplastic conditions, pre-neoplastic conditions and disrupted microbial community associated with the aforementioned conditions; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of inflammation, neuro-inflammation, and autoimmune diseases and disrupted microbial community associated with the aforementioned conditions; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of allergies and disrupted microbial community associated with allergies; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of metabolic disorders and disrupted microbial community associated with the aforementioned conditions; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases and disrupted microbial community associated with the aforementioned conditions; live bacteria, inactivated bacteria, recombinant bacteria and bacterial extracts; biological preparations in the nature of microorganisms to prevent disease in the nature of neoplastic conditions and pre-neoplastic conditions in animal or human subjects; biological preparations in the nature of microorganisms to prevent disease in the nature of inflammation, neuro-inflammation, and autoimmune diseases in animal or human subjects; biological preparations in the nature of microorganisms to prevent disease in the nature of allergies in animal or human subjects; biological preparations in the nature of microorganisms to prevent disease in the nature of metabolic disorders in animal or human subjects; biological preparations in the nature of microorganisms to prevent disease in the nature of cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases; biological preparations in the nature of microorganisms to treat and cure neoplastic conditions and pre-neoplastic conditions in animal or human subjects; biological preparations in the nature of microorganisms to treat and cure inflammation and autoimmune diseases in animal or human subjects; biological preparations in the nature of microorganisms to treat and cure allergies in animal or human subjects; biological preparations in the nature of microorganisms to treat and cure metabolic disorders and cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases in animal or human subjects; biological preparations in the nature of microorganisms to maintain and restore health in animal or human subjects via treatment of inflammation, neuro-inflammation, autoimmune diseases, allergies, metabolic disorders, cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases; biological preparations in the nature of microorganisms to maintain and restore health in animal or human subjects via treatment of neoplastic conditions and pre-neoplastic conditions; cultures of microorganisms and preparation of microorganisms in the nature of bacterial and bacteriological preparations, all for medical and veterinary purposes, the foregoing for medical purposes; vaccines; therapeutic vaccines; vaccine preparations.

Class [42]
Computer & Software Services & Scientific Services


Medical research; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines.

Mark Details


Serial Number

UK00918169875

Mark Type

Word

Kind of mark

Individual